Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: A north central cancer treatment group-based exploratory study

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1346-1353

  Adjei, Araba A ^a   Salavaggione, Oreste E ^a   Mandrekar, Sumithra J ^b   Dy, Grace K ^a   Ziegler, Katie L Allen ^b   Endo, Chiaki ^c   Molina, Julian R ^a   Schild, Steven E ^d   Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c TOHOKU UNIVERSITY   (Japan)

^d MAYO CLINIC   (United States)

Author keywords

Non small cell lung cancer; Pemetrexed; Polymorphisms; Reduced folate carrier gene; SLC19A1

Indexed keywords

ALANINE AMINOTRANSFERASE; FOLIC ACID; GEMCITABINE; PEMETREXED;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DYSPNEA; EXON; FATIGUE; FEMALE; FPGS GENE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GGH GENE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLC19A1 GENE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

EID: 77956268512     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ec18c4     Document Type: Article

References (32)

1. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier-and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48:459-471.
2. Wang Y, Zhao R, Goldman ID. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 2004;10:6256-6264.
3. Theti DS, Jackman AL. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004;10:1080-1089.
4. Habeck LL, Shih C, Gossett LS, et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,lO-dideazatetrahydrofolate analogs. Mol Pharmacol 1995;48:326-333.
5. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimi- dine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
6. Schneider E and Ryan TJ. Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta 2006;374:25-32.
7. Schilsky RL. Antimetabolites. In MC Perry, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins, 1992. Pp. 301-315.
8. Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-443.
9. Grem JL. Fluorinated pyrimidines. In BA Chabner, JM Collins, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia, PA: JB Lippincott, 1990, pp 180-224.
10. Cohen MH, Johnson JR, Wang YC, et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005;10:363-368.
11. Adjei AA. Pemetrexed (Alimta), a novel multitargeted antineoplasti- cagent. Clin Cancer Res 2004;10:4276S-4280S.
12. FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval. Available at: http://www.prnewswire.com/cgi-bin/micro-stories.pl?ACCT= 916306&TICK=LLY&STORY=/www/story/09-29-2008/0004893937&EDATE=Sep+29, +2008. Accessed January 15, 2010.
13. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89:1013-1018.
14. Gorlick R, Cole P, Banerjee D, et al. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamyla-tion. Adv Exp Med Biol 1999;457:543-550.
15. Wong SC, Zhang L, Witt TL, et al. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999;274:10388-10394.
16. Rhee MS, Wang Y, Nair MG, et al. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 1993;53:2227-2230.
17. Liani E, Rothem L, Bunni MA, et al. Loss of folylpoly-gamma-gluta-mate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-599.
18. Ma CX, Nair S, Thomas S, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-5937.
19. Leil TA, Endo C, Adjei AA, et al. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 2007;67:8772-8782.
20. Tang K, Fu DJ, Julien D. et al. Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 1999;96:10016-10020.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
23. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacoki-netic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127.
24. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008;8:129-138.
25. Chew HK, Doroshow JH, Frankel P, et al. Phase II studies of gemcit-abine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009;27:2163-2169.
26. Hildebrandt MA, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857-871.
27. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8: 132-138.
28. Côté JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007;13:3269-3275.
29. Adjei AA, Mandrekar SJ, Dy GK, et al. A phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small cell lung cancer (NSCLC): an NCCTG and SWOG Study N0426. J Clin Oncol 2010;28;614-619.
30. Laverdière C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-3834.
31. Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001;11:3416-3422.
32. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045.